Advertisement

Paul A. DiSilvestro, MD, on Ovarian Cancer: New Data on Olaparib in Newly Diagnosed Disease
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
00:00
00:00
00:00
 

Paul A. DiSilvestro, MD, on Ovarian Cancer: New Data on Olaparib in Newly Diagnosed Disease

ESMO Congress 2022

Advertisement

Paul A. DiSilvestro, MD, of Women & Infants Hospital and the Warren Alpert Medical School of Brown University, discusses overall survival results after a 7-year follow-up of the SOLO1/GOG-3004 trial for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. Dr. DiSilvestro details the increasing role of such PARP inhibitors in ovarian cancer treatment and their benefit to patients (Abstract 517O).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The objective of the SOLO1 trial was to determine the role of maintenance elaborate versus placebo in the treatment of women with advanced ovarian cancer in a BRCA a mutation. This trial completed enrollment in 2015, and at the initial presentation in 2018, demonstrated a 70% risk reduction in terms of death or progression versus placebo. A follow-up survival analysis in 2020 demonstrated that the median progression-free survival for the olaparib arm was 56 months, compared to 13 months in the placebo arm, again, confirming the benefit at that time. Nearly half of women were progression free at five years, versus 20% in the placebo arm. The overall survival analysis, which we presented, was performed at the seven-year time point, which is a clinically-meaningful time point in ovarian cancer survival. There were 391 women in the trial, they were randomized two to one to maintenance olaparib versus placebo and treated for two years. I will note that despite only a two-year treatment cap, we have seen maintain benefit beyond that in the earlier analyses. In this analysis, we devised something called an alpha spend, which is really a statistical way of saying, "How much are you willing to invest in a time point which was not your pre-specified overall survival endpoint?" So in this trial, the pre-specified overall survival has been determined to occur at 60% data maturity. In this trial, we're at 38% data maturity, so our alpha spend was .0001, or that we needed to be less than that for a p-value to determine statistical significance. So from a result perspective, maintenance olaparib has not yet reached its overall survival median. The median overall survival for the placebo arm was 75 months, and our hazard ratio was .55, which is a 45% reduction in risk of death at seven years after the last patient was randomized. If you look at it from a clinical perspective, 67% of women are alive seven years after their initial diagnosis, versus 45% in the placebo arm. In terms of the p-value, the p-value was 0.0004, which does not meet the level of statistical significance generated by our earlier alpha spend. Other analyses that we perform include something called time to first subsequent therapy, which is really a proxy for progression-free survival. So if you look at the women who are surviving in this trial, they're not only surviving, but the majority are surviving without actually having had a subsequent therapy, meaning they've had nothing beyond their initial treatment. Time to second subsequent therapy, which is really an indicator of, "Do you benefit beyond your first subsequent therapy?" And that was shown to be true, as well, favoring maintenance olaparib. We didn't see any new safety signals. We've been following the risk of MDS or AML, as well as new primary malignancies for the entirety of the trial, along with survival. And really, there's only been one new case that MDS or a AML in each arm, and new primary malignancies remain well balanced. There are no new adverse event signals, as well. So in summary, the SOLO1 trial demonstrated that maintenance olaparib provides a clinically meaningful benefit for women with advanced-stage ovarian cancer in a BRCA mutation. What does that mean for our practice of G1 oncology? It means that we need to be aware of germline and somatic BRCA status. We need to know that information so that when we make choices of maintenance therapy for our patients, we can utilize beneficial drugs, such as olaparib, to help improve their overall outcomes.

Related Videos

Breast Cancer
Immunotherapy

Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Nivolumab Monotherapy or in Combination Therapy

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, discusses the initial results from the BELLINI trial, which tested whether short-term preoperative nivolumab, either as monotherapy or in combination with low-dose doxorubicin or novel immunotherapy combinations, can induce immune activation in patients with early-stage triple-negative breast cancer with tumor-infiltrating lymphocytes (Abstract LBA13).

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Recent Phase III Data on Cabozantinib, Nivolumab, and Ipilimumab From the COSMIC-313 Trial

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss phase III findings showing that cabozantinib in combination with nivolumab and ipilimumab reduced the risk of disease progression or death compared with the combination of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma of IMDC (the International Metastatic RCC Database Consortium) intermediate or poor risk. However, the combination of cabozantinib, nivolumab, and ipilimumab vs nivolumab plus ipilimumab did not demonstrate an overall survival benefit to patients (Abstract LBA8).

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab

Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase III results from the IFCT-1701 trial of nivolumab plus ipilimumab 6-month treatment vs treatment continuation (LBA54 and Abstract 972O).

Skin Cancer
Immunotherapy

Sapna P. Patel, MD, on Melanoma: New Data on Pembrolizumab, Adjuvant vs Neoadjuvant Plus Adjuvant

Sapna P. Patel, MD, of The University of Texas MD Anderson Cancer Center, discusses the latest findings from the SWOG S1801 trial, which showed that using single-agent pembrolizumab as neoadjuvant therapy improved event-free survival compared to adjuvant therapy in high-risk resectable stage III–IV melanoma (Abstract LBA6).

Breast Cancer
Genomics/Genetics

Antonio Marra, MD, on Metastatic Breast Cancer: Patterns of Genomic Instability and Their Effect on Treatment

Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or without CDK4/6 inhibition in patients with estrogen receptor–positive/HER2-negative metastatic breast cancer (Abstract 210O).

Advertisement

Advertisement




Advertisement